LOGIN
ID
PW
MemberShip
2025-02-07 04:23
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
China rises as global R&D leader, K-bio not in top 50
by
Cha, Jihyun
Feb 6, 2025 05:57am
The R&D investment gap between Korean biopharmaceutical companies and Big Pharma is increasing. Analysis suggests that Korean companies must seek measures to respond to competition for next-generation technology as the R&D investment centers around the United States and China. On February 5, the Korea Chamber of Commerce and Industry (KCCI) a
Policy
Daewon to sell AZ¡¯s Symbicort in Korea
by
Lee, Tak-Sun
Feb 6, 2025 05:56am
Daewon Pharmaceutical will start selling AstraZeneca's asthma inhaler Symbicort (budesonide + formoterol fumarate hydrate) in Korea. The move is expected to expand the company's asthma inhaler lineup in addition to its existing Compona and expand the company¡¯s market share. According to industry sources, Daewon Pharmaceutical will start
Company
Baxter¡¯s Renal Care Unit spinoff Vantive is launched
by
Whang, byung-woo
Feb 6, 2025 05:56am
With the acquisition process complete for Baxter's Renal Care business, it has newly launched as Vantive, a new company specializing in kidney and life-sustaining organ therapies. The spin-off follows the acquisition of Baxter's Kidney Care business by funds managed by global investment firm The Carlyle Group. As an independent company
Company
Imminent launch of the 3rd new CAR-T-cell therapy 'Yescarta'
by
Eo, Yun-Ho
Feb 6, 2025 05:56am
The third CAR-T-cell therapy 'Yescarta' is expected to be commercialized in South Korea. According to industry sources, Gilead Sciences submitted documentation for the approval of the CAR-T-cell therapy, Yescarta (axicabtagene ciloleucel), and the Ministry of Food and Drug Safety (MFDS) is currently conducting the review. Yescarta was
Policy
Imlunestrant becomes first reviewed after new drug approval
by
Lee, Hye-Kyung
Feb 6, 2025 05:56am
The first application for a new drug license has been submitted since the fee for drug approval was raised to KRW 410 million. According to industry sources on the 6th, the multinational pharmaceutical company Eli Lilly applied for an marketing authorization for its breast cancer drug 'Inrulio (imlunestrant)' to the Ministry of Food and D
Policy
Reimb imminent for switching between atopic dermatitis drugs
by
Lee, Tak-Sun
Feb 5, 2025 05:53am
Switching between atopic dermatitis drugs may be reimbursed soon. This is because the National Health Insurance Service has completed its review through the preliminary drug price reduction system, and all that remains is the National Health Insurance Service's negotiations. As the expected claim amount is not large, the negotiations are e
InterView
"High hopes for reimbursed Ilaris¡¦a new treatment option"
by
Whang, byung-woo
Feb 5, 2025 05:52am
The Hereditary Periodic Fever (HPF) syndromes cause not just fever and pain but affect various aspects, such as patient's growth and development, psychological elements. The reimbursement coverage of a new treatment in nine years has increased patient satisfaction." Clinical practices have high hopes for changes to the treatment setting as Il
Policy
Low-dose nicergoline continues to be popular
by
Lee, Hye-Kyung
Feb 5, 2025 05:52am
Although it does not indicate the primary treatment of dementia, companies continue to receive approval for their low-dose nicergoline products. . The Ministry of Food and Drug Safety (MFDS) approved Reyon Pharm¡¯s ¡®Nicechol Tab. 10mg¡¯ on the 3rd. This is the second approval this year, following the approval of the ¡®Neurogoline Tab. 10mg¡¯
Company
1st to exceed KRW 1T sales¡¦Pfizer's ESG initiatives
by
Whang, byung-woo
Feb 5, 2025 05:52am
Pfizer Korea, the first to exceed KRW 1 trillion in sales from COVID-19 vaccine¡¤treatments, continues strengthening its sustainable business management based on the ESG initiative. After recording KRW 3 trillion in 2022 during the COVID-19 pandemic, Pifzer Korea's sales robustly decreased. However, despite unusual circumstances, the i
Company
Multiple sclerosis drug Ocrevus may soon be reimbursed
by
Eo, Yun-Ho
Feb 5, 2025 05:52am
The new multiple sclerosis drug Ocrevus is expected to be listed for reimbursement in Kore. According to industry sources, Roche Korea has completed negotiations with the National Health Insurance Service on the drug price of Ocrevus (ocrelizumab) for relapsing multiple sclerosis (MS). As a result, the drug is expected to be reimbursed
1
2
3
4
5
6
7
8
9
10
>